Skip to main content
IVVD logo

IVVD · Invivyd, Inc.

Track IVVD — free
$0.72 +0.04 (+5.13%) At close · Aug 14
Market Cap
$212.49M
Shares
294.76M

Invivyd, Inc. Earnings Call Transcripts

Every quarterly earnings call for Invivyd, Inc. (IVVD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-13
Invivyd, Inc. Q2 FY2026 Earnings Call
Revenue
$14.29M
▲ 21.2% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
Invivyd, Inc. Q1 FY2026 Earnings Call
Confident tone Public education and messaging Monoclonal antibody platform strategy Pivotal program recruitment and timing
Revenue
$13.74M
▲ 21.6% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-09
Invivyd Revolution Program & Measles Update Conference Call
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-05
Invivyd, Inc. Q4 FY2025 Earnings Call
Positive tone VYD-2311 COVID Prophylaxis Program Pemgarda Commercial Performance RSV Antibody Program
Revenue
$17.21M*
▲ 24.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Invivyd, Inc. Q3 FY2025 Earnings Call
Confident tone VYD2311 pivotal program Discovery pipeline (RSV, nasal antibodies, measles) PEMGARDA commercial franchise
Revenue
$13.13M
▲ 41.2% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-10-30
Invivyd REVOLUTION Pivotal Program Conference Call
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-15
Invivyd, Inc. Q1 FY2025 Earnings Call
Confident tone SARS-CoV-2 epitope durability Regulatory strategy and EUA-to-BLA path PEMGARDA commercial transition and growth
Revenue
$11.30M
Diluted EPS
$-0.14
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Invivyd, Inc. Q4 FY2024 Earnings Call
Revenue
$13.82M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Invivyd, Inc. Q3 FY2024 Earnings Call
Cautious tone FDA/regulatory headwind and KP.3.1.1 susceptibility issue Pemivibart (PEMGARDA) clinical efficacy and CANOPY data Treatment EUA / immunobridging regulatory pathway
Revenue
$9.30M
Diluted EPS
$-0.51
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Invivyd, Inc. Q2 FY2024 Earnings Call
Positive tone Immunocompromised patient population and unmet need PEMGARDA commercial launch and net revenue Pipeline molecule VYD2311
Revenue
$2.26M
Diluted EPS
$-0.40
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Invivyd, Inc. Q1 FY2024 Earnings Call
Confident tone PEMGARDA commercial launch Treatment opportunity and competition Regulatory pathway and FDA alignment
Revenue
$
Diluted EPS
$-0.38
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Invivyd, Inc. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Invivyd, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.36
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Invivyd, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.46
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Invivyd, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.32
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Invivyd, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Invivyd, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.42
Audio Transcript Slides 8-K10-Q
Showing 1–18 of 18 earnings calls
Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 128 filings 125 filers Visit website Investor relations